Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

A Single-arm Study Sponsored by Investigators to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Recurrent IgG4-related Diseases

This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

This study includes three stages: screening period, treatment period and safety follow-up period.

Inclusion Criteria:

• ≥18 years, male and female.
• With IGG4-related disease.

Exclusion Criteria:

• Inoculate live vaccine within 4 weeks before screening.
• Treponema pallidum antibody positive in screening period.
• Active hepatitis in screening period.
• With a history of solid organ or cell transplantation within 6 months before screening.
• With other medical or non-medical conditions that are not suitable for the study by the investigator.